Kalbe Farma KLBF IJ -Buy- Transforming the brand
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Consumer Durables SH JW SC 4.2K 13th Sep, 2024
Maintain Reduce, TP cut to IDR2,000; roll forward base year to FY25F with lower P/E of 17.2x
Market share deterioration persists
As mentioned in our previous reports, Indonesia local FMCG companies have outperformed foreign companies on several fronts, such as: 1) distribution, 2) advertising, 3) product variety, and 4) pricing strategy. Hence, we believe foreign FMCG companies, including UNVR, may continue to suffer market share erosion. Specifically for UNVR, we opine that previous management’s (which was at the helm of the company from 2014 to 2022) modifications to the sales team structure may have caused loss of talent. Moreover, the same management materially increased the number of third-party distributors, likely leading to higher levels of inventory. More importantly, we believe that UNVR HQ’s focus on margins likely came at the expense of market share; and, coupled with the royalty structure and relatively slow decision-making process also likely led to some inefficiencies. Going forward, with a new management team now in place, we believe it will take time to turn around the business, and we note that strategies such as price cuts and promotions may not yield results quickly, as local competitors may respond to counter these accordingly (read our previous report).
Cost-cutting programs may cause higher staff turnover
With Unilever PLC (ULVR LN, Not rated) having announced that it would cut jobs globally (link), we believe its Indonesia operations under UNVR might also face similar restructuring. We believe this situation, if materializes, may cause higher staff turnover in 2H24F, which could negatively affect sales performance. That said, if this strategy is executed carefully, we expect UNVR to gain from long-term benefits, such as creating a leaner organizational structure and at the same time retaining its best talents, which could then spur productivity.
Maintain Reduce; TP lowered to IDR2,000, implying 8% downside
We cut FY24F/FY25F/FY26F EPS by 10%/16%/17% due to market share erosion as well as relatively ineffective price cuts and A&P strategy. We maintain our Reduce call with a lower TP of IDR2,000 (from IDR2,670); we roll forward our base year to FY25F with a lower target P/E of 17.2x (-2.5SD to its three-year mean). Currently, the stock is trading at 18.9x FY25F P/E (EPS: IDR115.8).
| Year-end 31 Dec | FY23 | FY24F | FY25F | FY26F | |||
| Currency (IDR) | Actual | Old | New | Old | New | Old | New |
| Revenue (bn) | 38,611 | 39,898 | 37,488 | 40,640 | 36,858 | 41,601 | 37,735 |
| Reported net profit (bn) | 4,801 | 5,080 | 4,593 | 5,284 | 4,418 | 5,380 | 4,448 |
| Normalised net profit (bn) | 4,801 | 5,080 | 4,593 | 5,284 | 4,418 | 5,380 | 4,448 |
| FD normalised EPS | 125.84 | 133.15 | 120.40 | 138.50 | 115.80 | 141.03 | 116.59 |
| FD norm. EPS growth (%) | -10.4 | 5.8 | -4.3 | 4.0 | -3.8 | 1.8 | 0.7 |
| FD normalised P/E (x) | 17.4 | – | 18.2 | – | 18.9 | – | 18.8 |
| EV/EBITDA (x) | 12.3 | – | 12.7 | – | 13.0 | – | 13.0 |
| Price/book (x) | 24.7 | – | 24.4 | – | 24.4 | – | 24.4 |
| Dividend yield (%) | 5.7 | – | 5.4 | – | 5.3 | – | 5.3 |
| ROE (%) | 130.1 | 149.1 | 134.9 | 153.9 | 128.9 | 156.8 | 129.8 |
| Net debt/equity (%) | net cash | net cash | net cash | net cash | net cash | net cash | net cash |
Income statement (IDRbn) | |||||||||||||||||||
Year-end 31 Dec | FY22 | FY23 | FY24F | FY25F | FY26F | ||||||||||||||
Revenue | 41,219 | 38,611 | 37,488 | 36,858 | 37,735 | ||||||||||||||
Cost of goods sold | -22,154 | -19,417 | -18,943 | -18,651 | -19,024 | ||||||||||||||
Gross profit | 19,065 | 19,195 | 18,546 | 18,208 | 18,711 | ||||||||||||||
SG&A | -11,995 | -12,915 | -12,584 | -12,474 | -12,938 | ||||||||||||||
Employee share expense | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Operating profit | 7,070 | 6,279 | 5,962 | 5,734 | 5,772 | ||||||||||||||
EBITDA | 7,881 | 6,683 | 6,526 | 6,380 | 6,377 | ||||||||||||||
Depreciation | -811 | -404 | -564 | -646 | -605 | ||||||||||||||
Amortisation | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
EBIT | 7,070 | 6,279 | 5,962 | 5,734 | 5,772 | ||||||||||||||
Net interest expense | -84 | -77 | 3 | 4 | 4 | ||||||||||||||
Associates & JCEs | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other income | -1 | 0 | 0 | 0 | 0 | ||||||||||||||
Earnings before tax | 6,985 | 6,202 | 5,965 | 5,737 | 5,776 | ||||||||||||||
Income tax | -1,629 | -1,401 | -1,372 | -1,320 | -1,329 | ||||||||||||||
Net profit after tax | 5,356 | 4,801 | 4,593 | 4,418 | 4,448 | ||||||||||||||
Minority interests | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other items | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Preferred dividends | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Normalised NPAT | 5,356 | 4,801 | 4,593 | 4,418 | 4,448 | ||||||||||||||
Extraordinary items | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Reported NPAT | 5,356 | 4,801 | 4,593 | 4,418 | 4,448 | ||||||||||||||
Dividends | -5,341 | -4,753 | -4,547 | -4,418 | -4,448 | ||||||||||||||
Transfer to reserves | 15 | 48 | 46 | 0 | 0 | ||||||||||||||
Valuations and ratios | |||||||||||||||||||
Reported P/E (x) | 15.6 | 17.4 | 18.2 | 18.9 | 18.8 | ||||||||||||||
Normalised P/E (x) | 15.6 | 17.4 | 18.2 | 18.9 | 18.8 | ||||||||||||||
FD normalised P/E (x) | 15.6 | 17.4 | 18.2 | 18.9 | 18.8 | ||||||||||||||
Dividend yield (%) | 6.4 | 5.7 | 5.4 | 5.3 | 5.3 | ||||||||||||||
Price/cashflow (x) | 10.9 | 12.9 | 19.0 | 18.5 | 18.4 | ||||||||||||||
Price/book (x) | 20.9 | 24.7 | 24.4 | 24.4 | 24.4 | ||||||||||||||
EV/EBITDA (x) | 10.6 | 12.3 | 12.7 | 13.0 | 13.0 | ||||||||||||||
EV/EBIT (x) | 11.8 | 13.1 | 13.9 | 14.5 | 14.3 | ||||||||||||||
Gross margin (%) | 46.3 | 49.7 | 49.5 | 49.4 | 49.6 | ||||||||||||||
EBITDA margin (%) | 19.1 | 17.3 | 17.4 | 17.3 | 16.9 | ||||||||||||||
EBIT margin (%) | 17.2 | 16.3 | 15.9 | 15.6 | 15.3 | ||||||||||||||
Net margin (%) | 13.0 | 12.4 | 12.3 | 12.0 | 11.8 | ||||||||||||||
Effective tax rate (%) | 23.3 | 22.6 | 23.0 | 23.0 | 23.0 | ||||||||||||||
Dividend payout (%) | 99.7 | 99.0 | 99.0 | 100.0 | 100.0 | ||||||||||||||
ROE (%) | 128.8 | 130.1 | 134.9 | 128.9 | 129.8 | ||||||||||||||
ROA (pretax %) | 38.7 | 37.5 | 38.4 | 37.7 | 39.2 | ||||||||||||||
Growth (%) | |||||||||||||||||||
Revenue | 4.2 | -6.3 | -2.9 | -1.7 | 2.4 | ||||||||||||||
EBITDA | -6.6 | -15.2 | -2.4 | -2.2 | 0.0 | ||||||||||||||
Normalised EPS | -7.0 | -10.4 | -4.3 | -3.8 | 0.7 | ||||||||||||||
Normalised FDEPS | -7.0 | -10.4 | -4.3 | -3.8 | 0.7 | ||||||||||||||
Source: Company data, Nomura estimates | |||||||||||||||||||
Cashflow statement (IDRbn) | |||||||||||||||||||
Year-end 31 Dec | FY22 | FY23 | FY24F | FY25F | FY26F | ||||||||||||||
EBITDA | 7,881 | 6,683 | 6,526 | 6,380 | 6,377 | ||||||||||||||
Change in working capital | 1,499 | 1,275 | -751 | -550 | -502 | ||||||||||||||
Other operating cashflow | -1,714 | -1,478 | -1,369 | -1,316 | -1,325 | ||||||||||||||
Cashflow from operations | 7,667 | 6,480 | 4,405 | 4,514 | 4,551 | ||||||||||||||
Capital expenditure | -245 | -178 | -250 | -250 | 100 | ||||||||||||||
Free cashflow | 7,421 | 6,302 | 4,155 | 4,264 | 4,651 | ||||||||||||||
Reduction in investments | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Net acquisitions | 0 | 0 | 0 | 0 | |||||||||||||||
Dec in other LT assets | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Inc in other LT liabilities | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Adjustments | 110 | 53 | 56 | -82 | -7 | ||||||||||||||
CF after investing acts | 7,531 | 6,354 | 4,212 | 4,182 | 4,644 | ||||||||||||||
Cash dividends | -5,341 | -4,753 | -4,547 | -4,418 | -4,448 | ||||||||||||||
Equity issue | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Debt issue | -1,250 | -600 | 0 | 0 | 0 | ||||||||||||||
Convertible debt issue | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Others | -763 | -484 | 71 | -3 | 5 | ||||||||||||||
CF from financial acts | -7,354 | -5,837 | -4,477 | -4,420 | -4,443 | ||||||||||||||
Net cashflow | 178 | 518 | -265 | -239 | 201 | ||||||||||||||
Beginning cash | 325 | 503 | 1,021 | 756 | 517 | ||||||||||||||
Ending cash | 503 | 1,021 | 756 | 517 | 718 | ||||||||||||||
Ending net debt | 97 | -1,021 | -756 | -517 | -718 | ||||||||||||||
Balance sheet (IDRbn) | |||||||||||||||||||
As at 31 Dec | FY22 | FY23 | FY24F | FY25F | FY26F | ||||||||||||||
Cash & equivalents | 503 | 1,021 | 756 | 517 | 718 | ||||||||||||||
Marketable securities | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Accounts receivable | 4,416 | 2,719 | 2,909 | 2,860 | 2,928 | ||||||||||||||
Inventories | 2,625 | 2,422 | 2,363 | 2,326 | 2,373 | ||||||||||||||
Other current assets | 24 | 30 | 29 | 29 | 29 | ||||||||||||||
Total current assets | 7,568 | 6,192 | 6,057 | 5,732 | 6,049 | ||||||||||||||
LT investments | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Fixed assets | 9,536 | 9,311 | 8,997 | 8,601 | 7,896 | ||||||||||||||
Goodwill | 62 | 62 | 62 | 62 | 62 | ||||||||||||||
Other intangible assets | 447 | 399 | 443 | 535 | 528 | ||||||||||||||
Other LT assets | 705 | 700 | 600 | 590 | 604 | ||||||||||||||
Total assets | 18,318 | 16,664 | 16,159 | 15,520 | 15,139 | ||||||||||||||
Short-term debt | 600 | 0 | 0 | 0 | 0 | ||||||||||||||
Accounts payable | 4,700 | 4,064 | 4,209 | 3,730 | 3,459 | ||||||||||||||
Other current liabilities | 7,142 | 7,160 | 6,393 | 6,236 | 6,121 | ||||||||||||||
Total current liabilities | 12,442 | 11,224 | 10,602 | 9,966 | 9,580 | ||||||||||||||
Long-term debt | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Convertible debt | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other LT liabilities | 1,879 | 2,059 | 2,129 | 2,127 | 2,131 | ||||||||||||||
Total liabilities | 14,321 | 13,283 | 12,732 | 12,093 | 11,711 | ||||||||||||||
Minority interest | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Preferred stock | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Common stock | 76 | 76 | 76 | 76 | 76 | ||||||||||||||
Retained earnings | 3,825 | 3,209 | 3,255 | 3,255 | 3,255 | ||||||||||||||
Proposed dividends | 0 | 0 | 0 | 0 | 0 | ||||||||||||||
Other equity and reserves | 96 | 96 | 96 | 96 | 96 | ||||||||||||||
Total shareholders' equity | 3,997 | 3,381 | 3,427 | 3,427 | 3,427 | ||||||||||||||
Total equity & liabilities | 18,318 | 16,664 | 16,159 | 15,520 | 15,139 | ||||||||||||||
Liquidity (x) | |||||||||||||||||||
Current ratio | 0.61 | 0.55 | 0.57 | 0.58 | 0.63 | ||||||||||||||
Interest cover | 84.6 | 81.1 | – | – | – | ||||||||||||||
Leverage | |||||||||||||||||||
Net debt/EBITDA (x) | 0.01 | net cash | net cash | net cash | net cash | ||||||||||||||
Net debt/equity (%) | 2.4 | net cash | net cash | net cash | net cash | ||||||||||||||
Per share | |||||||||||||||||||
Reported EPS (IDR) | 140.40 | 125.84 | 120.40 | 115.80 | 116.59 | ||||||||||||||
Norm EPS (IDR) | 140.40 | 125.84 | 120.40 | 115.80 | 116.59 | ||||||||||||||
FD norm EPS (IDR) | 140.40 | 125.84 | 120.40 | 115.80 | 116.59 | ||||||||||||||
BVPS (IDR) | 104.78 | 88.63 | 89.83 | 89.83 | 89.83 | ||||||||||||||
DPS (IDR) | 140.00 | 124.59 | 119.19 | 115.80 | 116.59 | ||||||||||||||
Activity (days) | |||||||||||||||||||
Days receivable | 41.0 | 33.7 | 27.5 | 28.6 | 28.0 | ||||||||||||||
Days inventory | 41.8 | 47.4 | 46.2 | 45.9 | 45.1 | ||||||||||||||
Days payable | 76.4 | 82.4 | 79.9 | 77.7 | 69.0 | ||||||||||||||
Cash cycle | 6.5 | -1.2 | -6.2 | -3.2 | 4.1 | ||||||||||||||
Source: Company data, Nomura estimates | |||||||||||||||||||
INVESTMENT RATINGS
A rating of ‘Buy’, indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of ‘Neutral’, indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of ‘Reduce’, indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of ‘Suspended’, indicates that the rating, target price, and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies. Securities and/or companies that are labelled as ‘Not Rated’ or ‘No Rating’ are not in regular research coverage. Benchmark is Indonesia Composite Index (‘IDX Composite’). A ‘Target Price’, if discussed, indicates the analyst’s forecast for the share price with a 12-month time horizon, reflecting in part of the analyst’s estimates for the company’s earnings, and may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market in general.
GENERAL DISCLOSURE/DISCLAIMER
This report is prepared by PT Verdhana Sekuritas Indonesia (“PTVSI”) a securities company registered in Indonesia, supervised by Indonesia Financial Services Authority (OJK) and a member of the Indonesia Stock Exchange (IDX).
This report is intended for client of PTVSI only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of PTVSI.
The research set out in this report is based on information obtained from sources believed to be reliable, but PTVSI do not make any representation or warranty as to its accuracy, completeness or correctness. The information in this report is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company (or companies) referred to in this report. Any information, valuations, opinions, estimates, forecasts, ratings or targets herein constitutes a judgment as of the date of this report is published, and there is no assurance that future results or events will be consistent.
This report is not to be construed as an offer or a solicitation of an offer to buy or sell any securities or financial products. PTVSI and its associates, its directors, and/or its employees may from time to time have interests in the securities mentioned in this report or it may or will engage in any securities transaction or other capital market services for the company (companies) mentioned herein.
ANALYST CERTIFICATION
The research analyst primarily responsible for the content of this report and certifies that the views about the companies including their securities expressed in this report accurately reflect his/her personal views. The analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.
RESTRICTIONS ON DISTRIBUTION
By accepting this report, the recipient hereof represents and warrants that you are entitled to receive such report in accordance with the restrictions and agrees to be bound by the limitations contained herein. Neither this report nor any copy hereof may be distributed except in compliance with applicable Indonesian capital market laws and regulations.
| Rating Remains | Reduce |
| Target price Reduced from IDR 2,670 | IDR 2,000 |
| Closing price 11 September 2024 | IDR 2,190 |
| Implied upside | -8.7% |
| Market Cap (USD mn) | 5,427.0 |
| ADT (USD mn) | 2.9 |
M cap (USDmn) | 5,427.0 |
Free float (%) | 15.0 |
3-mth ADT (USDmn) | 2.9 |
(%) | 1M | 3M | 12M |
Absolute (IDR) | -11.0 | -28.4 | -40.0 |
Absolute (USD) | -7.9 | -24.3 | -40.3 |
Rel to Jakarta Stock Exchange Composite Index | -17.9 | -41.6 | -51.5 |
Sandy Ham (sandy.ham@verdhana.id),
Jody Wijaya (jody.wijaya@verdhana.id)
Samuel Christian (samuel.christian@verdhana.id)
saya
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Based on our survey of distributors and wholesalers, MYOR's domestic sales may have grown
Our analysis of FMCG and retail sales data of companies we track across Indonesia suggests that Sulawesi,
AMRT has consistently outperformed its FMCG peers in terms of sales growth over the past decade
Indonesia is a young nation (110mn population are below 40yrs, based on BPS) as well as social media-savvy (th
Over its nearly 30-year history, ACES has faced numerous challenges, including intense competition and the dis